GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd.: Anil Raghavan Appointed MD & CEO

MANAGEMENT ▲ Positive Development LOW RISK
📅 Filed on BSE: 13 Jul 2026, 05:46 PM IST  ·  BSE ID: 4d0a73d4-8d2c-4dc8-b997-5c72082cf110
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has approved the retirement of one director and the appointment of the current CEO as Managing Director.
🤖 AI Summary
  • Director Dr. Rajamannar Thennati retires upon completion of his term.
  • Anil Raghavan appointed Managing Director and Chief Executive Officer.
  • Appointment is effective August 11, 2026, subject to member approval.
  • Raghavan is not related to any other director; no SEBI debarment.
🏢 How This Affects the Company
📈
Business Impact
The appointment of a new MD & CEO, who is also the current CEO, signals continuity in leadership and strategic direction.
⚙️
Operational Impact
The transition brings the CEO into the Managing Director role, potentially consolidating decision-making and operational oversight.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders at this time, other than to note the information.
👤
Who Is Affected
All shareholders are affected by changes in key management personnel, impacting governance and strategic oversight.
🔍
Management Signal
The appointment signals a desire for leadership continuity by elevating the existing CEO to the Managing Director role.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
21st Annual General Meeting on August 10, 2026.
Shareholder approval for MD & CEO appointment.
Announcement of new Senior Management team members.
LOW RISK Leadership transition is routine and internal, with no immediate adverse indicators.
💡 Investor Takeaway
Sun Pharma Advanced Research Company Ltd. announced board director retirement upon term completion and the appointment of current CEO Anil Raghavan as MD & CEO from August 11, 2026.
📅 Company Track Record
Sun Pharma Advanced Research Company Ltd. has recently seen changes in its senior management team, including retirements and internal succession in operational roles.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
Who is retiring from the Board of Directors of Sun Pharma Advanced Research Company Ltd.?
Dr. Rajamannar Thennati will retire from the Board of Directors upon completion of his term at the 21st AGM.
Who has been appointed as the new Managing Director and Chief Executive Officer of Sun Pharma Advanced Research Company Ltd.?
Mr. Anil Raghavan, currently the Chief Executive Officer, has been appointed as the Managing Director and Chief Executive Officer.
When will Anil Raghavan's appointment as MD & CEO be effective for Sun Pharma Advanced Research Company Ltd.?
The appointment will be effective from August 11, 2026, subject to member approval at the 21st Annual General Meeting.
Is Anil Raghavan related to any other director at Sun Pharma Advanced Research Company Ltd.?
No, Mr. Anil Raghavan is not related to any other director of the Company.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.